Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02656810 · ClinicalTrials.gov registry record · Phase 1
A Comparison Study of PF708 and Forteo in Healthy Subjects
A Phase 1 study of Osteoporosis, sponsored by Pfenex.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT02656810 is a Phase 1 study of Osteoporosis that has completed, run by Pfenex. The registered enrollment target is 70 participants, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02656810, a Phase 1 study of Osteoporosis, has completed, sponsored by Pfenex.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the pharmacokinetics (blood levels) of two teriparatide products, PF708 and Forteo, in healthy subjects.
Conditions Studied
Interventions
- DRUG Teriparatide
Study Locations (1)
Indiana
- Covance Clinical Research Unit - Evansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02656810
The ClinicalTrials.gov registry entry for NCT02656810 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (95% lower). The listed sponsor is Pfenex, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteoporosis appearing as the primary indexed condition, and to 1 intervention - of which Teriparatide is the first listed.
NCT02656810 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT02656810 about?
NCT02656810 is a clinical study titled "A Comparison Study of PF708 and Forteo in Healthy Subjects". The purpose of this study is to compare the pharmacokinetics (blood levels) of two teriparatide products, PF708 and Forteo, in healthy subjects.
What is the current status of trial NCT02656810?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2015-12. Estimated completion is 2016-07.
What conditions does trial NCT02656810 study?
This clinical trial studies the following conditions: Osteoporosis.
What interventions are being tested in trial NCT02656810?
The interventions under investigation include: Teriparatide (DRUG).
Who is sponsoring clinical trial NCT02656810?
This trial is sponsored by Pfenex, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02656810 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis
ACTIVE NOT RECRUITING · Phase 1
-
Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose
COMPLETED · Phase 1
-
Patient- and Physician-Based Osteoporosis Education
COMPLETED · Phase 1
-
Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects
COMPLETED · Phase 1
-
Improving Bone Health in Adolescent Girls: The Youth Osteoporosis and Understanding Total Health (YOUTH) Study
COMPLETED · Phase 1
-
A Safety, Tolerability and Pharmacodynamics Study of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.